Chronic Myelocytic Leukemia CML

Chronic myelocytic leukemia is the resulting disease when neutrophil, basophil, eosinophil, and monocyte progenitors become cancerous. It is usually caused by the presence of the Philadelphia chromo...

Fludarabine can't replace cyclophosphamide with busulfan myeloablative conditioning

NEW YORK (Reuters Health) - In patients with leukemia and myelodysplastic syndrome who need myeloablative conditioning before allogeneic hematopoietic cell transplantation (HCT), the less toxic...

In Waldenstrm macroglobulinemia, fludarabine yields better survival than chlorambucil

NEW YORK (Reuters Health) - Fludarabine improves survival compared with chlorambucil in patients with Waldenstrm macroglobulinemia (WM) and related disorders, according to the multicenter WM1 stud...

Human medicines European Public Assessment Report (EPAR): Busilvex, busulfan, Revision: 10, Authorised

Human medicines European Public Assessment Report (EPAR): Busilvex, busulfan, Revision: 9, Authorised

Busulfan Conditioning Enhances Engraftment of Hematopoietic Donor-derived Cells in the Brain Compared With Irradiation

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant

BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells

Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation

Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.

We examined pharmacokinetic-targeted IV busulfan (75-170 mg/m(2), with target AUC of 3500-6000 μmol min) and fludarabine (40 mg/m(2)) × 4 days with rituximab (t-IV Bu/Flu + rituximab) 375 ...

Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.

Personalizing intravenous (IV) busulfan doses in children using therapeutic drug monitoring (TDM) is an integral component of hematopoietic cell transplant. The authors sought to characterize initial...

Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).

The assessment of a hematopoietic stem cell transplant (HSCT)-specific comorbidity index (HCT-CI) has been developed to predict the risk of TRM in patients undergoing allogeneic HSCT. As the myeloabla...

Human B Cell Development and Antibody Production in Humanized NOD/SCID/IL-2Rγ(null) (NSG) Mice Conditioned by Busulfan.

BACKGROUND: Busulfan treatment as a chemotherapeutic agent has been considered an alternative approach in xenograft model because it offers a simple, convenient, effective, and less toxic conditioning...

Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.

In reduced intensity, allogeneic stem cell transplantation from unrelated donors (u-RIST), graft-versus-host disease (GVHD), graft failure, and non-relapse mortality (NRM) are persistent problems. Alt...